Warning
STUDY SUMMARY

STUDY SUMMARY: CPTAC CCRCC Confirmatory Study - Training - Metabolome

61
Cases
61
Aliquots
SUMMARY
PDC Study IdentifierPDC000534Analytical FractionMetabolome
Study ID7d40ea67-752b-4842-8252-0ef594c47617Disease TypesClear Cell Renal Cell Carcinoma;Non-Clear Cell Renal Cell Carcinoma;Other
Study NameCPTAC CCRCC Confirmatory Study - Training - MetabolomeProject IDCPTAC3 Discovery and Confirmatory
Experiment TypeLabel Free

Clear cell renal cell carcinomas (ccRCCs) represent ~75% of RCC cases and account for most RCC-associated deaths. Inter- and intra-tumoral heterogeneity (ITH) results in varying prognosis and treatment outcomes. Prior large-scale ccRCC studies evaluated either histologic variation or molecular profiles. To obtain a more comprehensive profile of ccRCC, we carried out integrative histopathologic, proteogenomic, and metabolomic analyses from 305 ccRCC tumor segments and 166 paired normal adjacent tissues from 213 cases. Combining histologic and molecular profiles revealed ITH in 90% of ccRCCs, with 50% demonstrating immune signature heterogeneity. High tumor grade along with BAP1 mutation, genome instability, increased hypermethylation, and a specific protein glycosylation signature defined a new high-risk disease subset, where UCHL1 expression displayed prognostic value. Single nuclei RNA-seq of the adverse sarcomatoid and rhabdoid phenotypes uncovered gene signatures and potential insights into tumor evolution. This study molecularly stratifies an aggressive ccRCC subtype that may inform more effective treatment strategies.


Raw Mass Spectra
Data CategoryFiles (n=142)
Raw Mass Spectra (Proprietary)142
External References
The Cancer Imaging ArchiveCPTAC-CCRCC
Database of Genotypes and Phenotypesphs001287
Imaging Data CommonsCPTAC-CCRCC
Genomic Data CommonsCPTAC-3
Related PDC studies
CPTAC CCRCC Discovery Study - DIA ProteomePDC000200
CPTAC CCRCC Confirmatory Study - DIA ProteomePDC000411
CPTAC CCRCC Confirmatory Study - DIA PhosphoproteomePDC000412
CPTAC CCRCC Confirmatory Study - DIA Intact GlycoproteomePDC000413
CPTAC CCRCC Confirmatory Study - Intratumor Heterogeneity - DIA ProteomePDC000414
CPTAC CCRCC Confirmatory Study - Kinase Inhibition - DIA PhosphoproteomePDC000415
CPTAC CCRCC Confirmatory Study - Validation - MetabolomePDC000535